Recent News

• 11.21.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 11.06.2025 - Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
• 11.03.2025 - Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
• 10.23.2025 - Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
• 10.17.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 09.19.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 09.19.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
• 09.15.2025 - InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.05.2025 - 2025 Wells Fargo Healthcare Conference

Recent Filings

• 11.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.12.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities